Skip to main content

UBS Group AG

Position in QNCX — Quince Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in QNCX

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$11,231
-$23,500,409 QoQ
Shares Held
556
-98.4% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#36
of 46 holders
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 32.55395683453237.ToString("F0")% Shared 0.ToString("F0")% None 67.44604316546763.ToString("F0")%

Common Shares in QNCX Over Time

Shares Held

Position Value (USD)

Derivatives in QNCX

reported options exposure · as of Sep 30, 2021
CallValue
$0
CallShares
0
PutValue
$920,266,400
PutShares
50,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. QNCX ranks #460 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in QNCX

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $11,231 556
2025-12-31 $23,511,640 35,092
2025-09-30 $479,872 1,472
2025-06-30 $939,180 2,846
2025-03-31 $187,796 706
2024-12-31 $416,636 1,114
2024-09-30 $74,496 480
2024-06-30 $72,000 480
2024-03-31 $107,060 505
2023-12-31 $106,050 505
2023-09-30 $1,493,632 6,668
2023-06-30 $274,512 912
2023-03-31 $101,400 325
2022-12-31 $5,843,710 45,869
2022-09-30 $8,858,864 33,304
2022-06-30 $11,154,612 25,123
2022-03-31 $31,675,468 25,586
2021-12-31 $39,505,648 15,652
2021-09-30 $920,266,400 50,200
2021-09-30 $311,460,680 16,990
2021-06-30 $107,547,600 10,146
2021-03-31 $258,090,096 35,816
2020-12-31 $58,638,024 10,554
2020-09-30 $203,710,000 20,371
2020-06-30 $212,563,300 22,955
2020-03-31 $237,847,028 26,074